|Audit||Nominating and Governance||Compensation|
|Fred Cohen,, MD., D.Phil.|
Fred E. Cohen, M.D., D.Phil. has served on our board of directors since June 2013. Dr. Cohen is a partner at TPG, a private equity firm he joined in 2001, and serves as co-head of TPG’s biotechnology group. Dr. Cohen served as a Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco, from 1988 until 2014. From 1995 to 2001, Dr. Cohen served as the Chief of the Division of Diabetes, Endocrinology and Metabolism in the Department of Medicine of UCSF. Dr. Cohen also serves as a director of Genomic Health (NASDAQ: GHDX), Roka Bioscience (NASDAQ: ROKA), CareDx (NASDAQ: CDNA), Quintiles Transnational Holdings (NYSE: Q), Five Prime Therapeutics (NASDAQ: FPRX), Biocryst (NASDAQ: BCRX) and Veracyte (NASDAQ: VCYT). In addition, Dr. Cohen serves as a director of several privately held companies. Dr. Cohen holds a B.S. in Molecular Biophysics and Biochemistry from Yale University, a D.Phil. in Molecular Biophysics from Oxford University and an M.D. from Stanford University.
|Howard Greene, Jr.|
|Jesse Treu,, Ph.D.|